# Synlogic

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/synlogic

- Industry: Pharmaceuticals
- Headquarters: Cambridge, US
- Website: www.synlogictx.com
- Total disclosed funding: $87M
- Latest round: Series C (May 15, 2017)
- Investors on record: 11

## About

Founded in 2014 and based in Cambridge, Massachusetts, Synlogic, Inc. focuses on developing innovative biotherapeutics utilizing synthetic biology to create transformative treatment options for various diseases.Synlogic, Inc. specializes in the creation of Synthetic Biotics, therapeutic solutions derived from engineered living organisms that target specific medical conditions. Founded in 2014 in Cambridge, Massachusetts, the company has executed 11 deals, with their latest funding round being a Private Placement/Follow on in April 2021, raising USD 45.00 mn, which is the total amount raised to date. The company is led by CEO Aoife Brennan, and was founded by Tim Lu, who has a history of founding other companies in the biotech sector.Synlogic Therapeutics develops innovative biotherapeutics through synthetic biology, focusing on their core product offerings known as Synthetic Biotics. These therapeutics are designed to address the underlying biological drivers of diseases, targeting conditions like phenylketonuria (PKU) and metabolic disorders, which could significantly enhance patient outcomes. They are marketed primarily to healthcare providers, biopharmaceutical partners, and research institutions across North America and Europe, aiming to meet high unmet medical needs.Synlogic Therapeutics generates revenue through strategic partnerships and collaborations with biopharmaceutical companies, advancing their proprietary therapeutics into clinical trials and potential commercialization. The company engages in B2B transactions, providing access to their Synthetic Biotics for clinical evaluation, which may involve structured agreements that outline research and development milestones, leading to potential licensing fees or royalties. Specific pricing plans for their products are not disclosed, but these partnerships typically include various financial arrangements aligned with the stages of therapeutic development.Looking ahead, Synlogic, Inc. aims to further develop its pipeline of Synthetic Biotics and plans to expand its market presence in Europe and North America by 2023. The recent funding raised from its April 2021 Private Placement, which amounted to USD 45.00 mn, will be utilized to support the advancement of their therapeutics and facilitate the launch of new products. This aligns with their strategy to enhance treatment options for patients suffering from metabolic disorders.

## Funding rounds

- Series C, May 15, 2017, $42M — Atlas Venture, New Enterprise Associates, OrbiMed Advisors, AJU IB Investment, Arctic Asset Management, Deerfield Management, Rock Springs Capital, Ally Bridge Group, Perceptive Advisors, CLI Ventures
- Series B, Feb 17, 2016, $40M — Atlas Venture, New Enterprise Associates, OrbiMed Advisors, Deerfield Management
- Series A, Sep 23, 2014, $0.5M — Atlas Venture, New Enterprise Associates, Bill & Melinda Gates Foundation
- Series A, Jul 7, 2014, $4M — Atlas Venture, New Enterprise Associates

## Investors

- Atlas Venture (https://capitalatlas.ai/funds/atlas-venture) — Series A, Series B, Series C
- New Enterprise Associates (https://capitalatlas.ai/funds/new-enterprise-associates) — Series A, Series B, Series C
- Bill & Melinda Gates Foundation — Series A
- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series B, Series C
- Deerfield Management (https://capitalatlas.ai/funds/deerfield-management) — Series B, Series C
- AJU IB Investment (https://capitalatlas.ai/funds/aju-ib-investment) — Series C
- Arctic Asset Management — Series C
- Rock Springs Capital — Series C
- Ally Bridge Group (https://capitalatlas.ai/funds/ally-bridge-group) — Series C
- Perceptive Advisors (https://capitalatlas.ai/funds/perceptive-advisors) — Series C
- CLI Ventures (https://capitalatlas.ai/funds/cli-ventures) — Series C